Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fatty acid synthesis-related long non-coding RNA (FASRL) (FASRL)
- Target
- FASRL
- Molecular classification
- Other (Long non-coding RNA)
01
Overview
Fatty acid synthesis-related long non-coding RNA (FASRL), also called NQO1 divergent transcript (NQO1-DT), is a lncRNA reportedly located near the NQO1 locus but does not encode the canonical NQO1 protein. FASRL has been implicated in the regulation of cellular fatty acid synthesis by modulating metabolic enzyme activity and acts as an oncogenic factor in certain malignancies, notably hepatocellular carcinoma. Its expression is correlated with poor prognosis in cancer patients and may serve as a potential target for RNA-based therapeutics. The use of "NQO1-DT" may cause confusion with the NAD(P)H:quinone oxidoreductase 1 enzyme, a well-established drug and disease target in cancer and neurological disorders; however, they are distinct in function and molecular class[1][2].
- Other names
- Fatty acid synthesis-related lncRNAFASRLNQO1 divergent transcript (NQO1-DT)
02
Mechanism of action
Inhibiting the transcript (e.g. antisense, siRNA) to downregulate fatty acid synthesis and tumorigenesis
03
Biological functions
Regulation of fatty acid synthesisModulation of gene expressionInfluence on cellular proliferation and tumor growth
04
Disease associations
CancerMetabolic disease (potential)
05
Safety considerations
Limited evidence on safety due to lack of clinical targeting; risk relates primarily to unintended modulation of metabolic pathways and associated toxicities
06
Biomarkers
Overexpression of FASRL/NQO1-DT in tumor tissue (proposed as prognostic indicator)
Beyond the preview
Go deeper on Fatty acid synthesis-related long non-coding RNA (FASRL) (FASRL).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fatty acid synthesis-related long non-coding RNA (FASRL) (FASRL).